Neil Kumar

Chairman of the Board at QED Therapeutics

Neil is the Chief Executive Officer and Founder of BridgeBio Pharma LLC, a company focused on the development of novel therapies for genetic diseases. Prior to founding BridgeBio, he held prominent roles with both established and emerging companies, including Principal at Third Rock Ventures, VP of Business Development and Operations for MyoKardia, and Associate Principal at McKinsey & Company. Additionally, Neil was involved in the formation of a gene chip startup and was a technical consultant for AstraZeneca’s pathway signaling group. Neil is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds BS and MS degrees in Chemical Engineering from Stanford University, and received his PhD in Chemical Engineering from the Massachusetts Institute of Technology.